ClinicalTrials.gg
Sign In
RecruitingNCT05292235Updated Oct 22, 2026

Perioperative Parameter and Treatment Outcomes of Surgical Treatment for Benign Prostate Hyperplasia in Hong Kong

An observational study in Benign Prostatic Hyperplasia, sponsored by Chinese University of Hong Kong. Recruiting at 3 sites in Hong Kong. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Chinese University of Hong Kong · Observational

From the registry’s dates

  • Started Apr 2022; still recruiting 4 years 7 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
Male
01

Study summary

This is a prospective data registry to assess the treatment outcomes and complications of different treatment approaches in our hospital clusters.

Read the detailed description

Benign prostatic hyperplasia (BPH) is a very common disease affecting men. Patients with BPH may present with voiding symptoms including hesitancy, intermittence, slow stream and sensation of incomplete emptying, and storage symptoms including urinary frequency, urgency and nocturia. Patients may also suffer from complications including urinary retention, recurrent urinary tract infection, bladder stone formation and obstructive uropathy. For patients who have lower urinary tract symptoms refractory to medications, or those who suffer from complications of BPH, transurethral prostatectomy should be considered.

Surgical intervention options have evolved from electrosurgical resection to the use of lasers for enucleation and ablation [1]. Aquablation and Rezum system are new minimally invasive surgical technology for BPH management. [2,3,4]. Different treatment approaches will result in different treatment successful rate and also potential adverse effects to patients.

However, large-scale studies investigating the different modalities of surgical treatment of BPH are lacking. Therefore, a prospective data registry is created to assess the perioperative surgical outcomes for different surgical treatment of BPH.

02

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

03

In context

Prostatic Hyperplasia

827 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 250 across 177 observational studies indexed under Prostatic Hyperplasia.

Browse Prostatic Hyperplasia studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,454 studies on the registry; 474 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Chinese University of Hong Kong studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with BPH and planned for surgery (including all type of endoscopic procedures) in the hospitals will be identified and then enrolled to the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient at the age of 18 or above

Exclusion criteria

Exclusion Criteria:

  • Patient is unable to give consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. International Prostate Symptom Score (IPSS) questionnaire total Score

    Change in total scores in International Prostate Symptom Score (ranges from 0 to 35) questionnaires

    Time frame: Baseline, 3 months after surgical treatment for BPH

  2. Voiding function in uroflowmetry

    Change in urodynamic function assessed by Uroflowmetry

    Time frame: Baseline, 3 months after after surgical treatment for BPH

Secondary outcomes

  1. Complication after surgical treatment

    The 30-day complications will be graded according to the Clavien-Dindo classification

    Time frame: Post operation 30 days after surgical treatment for BPH

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Kahokehr A, Gilling PJ. Landmarks in BPH--from aetiology to medical and surgical management. Nat Rev Urol. 2014 Feb;11(2):118-22. doi: 10.1038/nrurol.2013.318. Epub 2014 Jan 21. PubMed 24445912 ↗
  • Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, Stief CG, Woo HH, Gratzke C. Emerging Minimally Invasive Treatment Options for Male Lower Urinary Tract Symptoms. Eur Urol. 2017 Dec;72(6):986-997. doi: 10.1016/j.eururo.2017.07.005. Epub 2017 Jul 19. PubMed 28734706 ↗
  • Faber K, de Abreu AL, Ramos P, Aljuri N, Mantri S, Gill I, Ukimura O, Desai M. Image-guided robot-assisted prostate ablation using water jet-hydrodissection: initial study of a novel technology for benign prostatic hyperplasia. J Endourol. 2015 Jan;29(1):63-9. doi: 10.1089/end.2014.0304. PubMed 25000418 ↗
  • Dixon CM, Rijo Cedano E, Mynderse LA, Larson TR. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezum((R)) system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol. 2015 Jan 30;7:13-8. doi: 10.2147/RRU.S74040. eCollection 2015. PubMed 25674555 ↗
  • Siu BWH, Leung DKW, Wong RSK, Wong CHM, Liu AQ, Yee CH, Teoh JYC, Chiu PKF, Ng CF, Lo KL. Thulium fiber laser enucleation of the prostate with SOLTIVE SuperPulsed laser systems: a prospective evaluation of early outcomes in an Asian cohort. Front Urol. 2026 Mar 30;6:1753089. doi: 10.3389/fruro.2026.1753089. eCollection 2026. PubMed 41983244 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Apr 2032, 120 months after the start.

Of 59 non-industry observational studies under Prostatic Hyperplasia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 50. This study's planned 120 months is above that.

Counting every sponsor, half of 74 studies reached it within 25 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2022
First posted
Mar 23, 2022
StartActual
Apr 1, 2022
Primary completionEst.
Apr 30, 2032
CompletionEst.
Jul 31, 2032
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41983244 ↗
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41983244 ↗
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05292235
Lead sponsor
Chinese University of Hong Kong
Responsible party
NG Chi Fai (Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Mar 23, 2022
Start date
Apr 1, 2022
Primary completion
Apr 30, 2032 (estimated)
Completion
Jul 31, 2032 (estimated)
Last update
Oct 22, 2026

Study contacts

Chi Fai NG, MD
Contact
ngcf@surgeryh.cuhk.edu.hk
35052625
Chi Fai NG, MD
principal investigator · Chinese University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Prostatic Hyperplasia →

Other studies from this sponsor

Chinese University of Hong Kong →

Start the discussion